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The aim of this review article is to report about the anti-inﬂammatory properties of
calcitonin gene–related peptide (CGRP) in burns. CGRP is a 37-amino acid neuropep-
tide, primarily released from sensory nerves and is well known as the most potent and
long-lasting microvascular vasodilator in vitro and hypotensive agents in vivo.
A wide range of proinﬂammatory stimuli can induce the release of neuropeptides
from cutaneous sensory nerves, including heat, physical trauma, UV radiation, and
irritant chemicals. These proinﬂammatory stimuli are known to induce the release of
CGRP from cutaneous sensory nerves. The anti-inﬂammatory effects of CGRP in a
range of species and in human clinical conditions are detailed, and potential thera-
peutic applications based on the use of antagonists and gene targeting of agonists are
discussed.
Thermal injury of the skin results in local tissue destruction and a systemic response.
The increased temperature kills cells in the immediate area and denatures the surrounding
extracellular matrix proteins. Earlier experimental investigations have shown that the in-
ﬂammatory reaction is divided into early and delayed phases. The ﬁrst phase is believed to
be due to the direct effect of heat on burned tissue causing an increased capillary ﬁltration
followed by edema formation.1 The second, or delayed phase, depends on a cascade of
mediators released by the local tissue and central nervous system, leading to physiological
changes including increased capillary hydrostatic pressure, leakage of intravascular ﬂuid
and proteins into the interstitium, decreased cardiac output, and suppression of the immune
system. This delayed reaction is induced by the contribution of sensory neuropeptides such
as calcitonin gene–related peptide (CGRP).2
CGRP is a 37-amino acid neuropeptide encoded by an alternative processing of the
calcitoningeneinthyroidCcells.3,4 Itisfoundinsensorypeptidergicnervesthatarepresent
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Figure 1. Relevance of calcitonin gene related peptide. Action in tissue
repair.
in most tissues and organ systems, including blood vessels, heart, kidney, gastrointestinal
system,andlymphoidorgans.CGRPiswellknowasapotentandlong-lastingmicrovascular
vasodilator in vitro and a hypotensive agent in vivo.5−11
CGRP can potentiate inﬂammatory edema in skin induced by mediators that in-
crease microvascular permeability.5 This is thought to be a consequence of its action as a
microvascular vasodilator.
CGRP has a proliferative effect on human endothelial cells; therefore, it is important
for the formation of new vessels, for example, in ischemia, inﬂammation, and the healing
of wounds; it is also regarded as an important modulator of the inﬂammatory response after
the activation of sensory nerves (Fig 1).2,12 The aim of this review article is to report the
anti-inﬂammatory properties of CGRP in burns.
BURN PATHOPHYSIOLOGY
Several investigations have focused on the circulatory and microcirculatory alterations
associated with burn shock and edema formation in both burned and nonburned tissues.
Under normal physiological conditions, blood pressure in the capillaries causes the
ﬁltrationofﬂuidintotheinterstitialspace.Thethermalinjurycausesextravasationofplasma
into the burn wound and the surrounding tissues. Edema develops when the ﬁltration rate
exceeds the ﬂow in the lymphatic vessels draining the same tissue. It follows a biphasic
pattern.Animmediateincreaseinwaterisseenintheﬁrsthourafterinjury.Asecondphase,
which is more gradual, occurs 12 to 24 hours after burn injury.13 Thermal injury causes
direct and indirect mediator-modulated changes of the permeability of blood tissue barrier
of the capillaries and venules. This pathophysiological response involves several classes
of chemical mediators14 interacting in a complex manner to cause the pain and secondary
tissue damage (Table 1).
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Table 1. Inﬂammatory mediators of burn
Mediators Effects Tissue effect References
Histamine ↓Blood pressure
Hypovolemia
Arteriolar dilation and
venular constriction
↑Blood ﬂow
↑Permeability
15–18
Prostaglandin E2 ↓Systemic arterial and
pulmonary arterial blood
pressure
Vasodilation
↑Blood ﬂow
↑Permeability
19, 20
Prostacyclin (PGI2) ↓Blood pressure ↑Permeability 21
Leukotriene B4
Leukotriene D4
Pulmonary hypertension Vasoconstriction of
pulmonary vessels
21
Tromboxane A2
Tromboxane B2
GI∗ ischemia
Pulmonary hypertension
Vasoconstriction
↑Permeability
19, 22–24
Bradykinin ↓Blood pressure
Hypovolemia
Vasodilation
↑Permeability
21, 25
Serotonin ↑Permeability 18
Catecholamine ↑Heart rate
↑Blood pressure
↑Metabolism
Vasoconstriction (α
receptors)
Vasodilation (β2 receptors
in muscle)
Block ↑ permeability due
to histamine and
bradykinin (β receptors)
17, 21, 26
Oxygen radicals Cardiac dysfunction Tissue damage
↑Permeability
15, 16, 21, 27
Platelet aggregation factor ↑Blood pressure Vasoconstriction 28–30
Angiotensin II GI ischemia
↑Blood pressure
Vasoconstriction 31
Vasopressin GI ischemia
↑Blood pressure
Vasoconstriction 32
Procalcitonin 33, 34
Antimicrobial peptides
(defensins and
cathelicidins)
Protective role against
microbes
35–37
Tachykinins
Substance P
Neurokinin A
Neurokinin B
Edema Vasodilation
↑Permeability
38–43
Calcitonin gene–related
peptide
↑Heart rate
↓Blood pressure
Vasodilation
↑Permeability
Proliferative effect on
human endothelium
38, 44
∗GI indicates gastrointestinal.
SENSORY NERVOUS SYSTEM AND INFLAMMATION
There is evidence that the activation of the peripheral nervous system generates the major
features of inﬂammation. The so-called “neurogenic inﬂammation” is mainly due to the
activation of C-ﬁbers45 and Aδ-ﬁbers,46,47 leading to erythema, wheal, and ﬂare.48
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It is also accepted that these symptoms are due to antidromic release of sensory
neuropeptides, in which tachykinins, such as substance P (SP), neurokinin (NK) A, and
NKB together with CGRP, play a major role.48−54
The neurogenic inﬂammatory response is complex and cannot simply be regarded
as a series of neuronal events occurring in isolation. Indeed, it is known that the initia-
tion and sustenance of neurogenic inﬂammation depend on a variety of factors, such as
endothelium, kininogens, and neuropeptides, present in the local environment. The va-
sodilation response characteristic of neurogenic inﬂammation requires the presence of
endothelium and is linked to the production of nitric oxide (NO).55 It has been suggested
that NO may act prejunctionally or within peripheral neurons to mediate the release of
neuropeptides during neurogenic inﬂammation within the skin microvasculature.56,57 In
the course of inﬂammation, ubiquitous kininogens, including bradykinin, are important
mediators of inﬂammation. In addition to direct activation and sensitization of nocicep-
tors, there is evidence that kinins are proinﬂammatory, leading to vasodilation, plasma
extravasation, and the release of other inﬂammatory mediators, notably the neuropeptides
SP and CGRP.58 The ﬁnding that the pungent extract of the Hungarian pepper, capsaicin
(8-methyl-N-vanillyl-6-noneamide), can be used as a neurotoxin for the nonmyelinated
sensory afferents59 is of crucial importance to research on the role of the nervous system
in the inﬂammatory process. Capsaicin is selective for the stimulation and blockage of a
subset of mammalian afferent neurons of dorsal root ganglia with C- and Aδ-ﬁbers. In
response to stimulation, peptide mediators are released from the central and peripheral
nerve endings of these neurons, and both SP and CGRP are involved in the capsaicin-
induced reaction. SP induces a short-lasting endothelium-dependent vasodilation through
the activation of the NKI receptor,60 which is partly dependent on NO release.61 SP also
causes plasma protein extravasation62,63 and a concomitant histamine release from mast
cells.64−67
The most prominent features of the neurogenic inﬂammation are vasodilation. CGRP,
most often co-released with SP, is the most potent endogenous vasodilator found in an-
imals and humans5,68 and the most abundant neuropeptide in the peripheral nervous
system.
CALCITONIN GENE–RELATED PEPTIDE
CGRPwasidentiﬁedin1982whenRosenfeldetal4 showedthatalternativeRNAprocessing
of the calcitonin gene generated mRNAs encoding a peptide they named CGRP. It is highly
expressed in certain nerves and is now known to belong to a family that includes the
more recently discovered peptides adrenomedullin and amylin. This group belongs to a
larger family of peptides that includes calcitonin. Calcitonin is a potent inhibitor of bone
resorption, acting via receptor-mediated inhibition of osteoclast function.69 The overall
effect of CGRP on bone resorption is unclear, although it can inhibit osteoclast activity,70
but it is best known for its potent cardiovascular effects.71 CGRP is distributed throughout
the central and peripheral nervous systems and exhibits a range of biological effects on
tissues including those associated with gastrointestinal, respiratory, endocrine, and central
nervous systems (Fig 2).63,72−78
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Figure 2. The CGRP gene is expressed in the dorsal root ganglion (DRG) and is upregulated by
factors that include nerve growth factor (NGF) and tissue inﬂammation. CGRP is released from
nerves in response to several stimuli, such as capsaicin and low pH, proteinase-activated receptor
(PAR activation), and mediators (eg, kinins and prostaglandins [PG]). Opioids can inhibit the
release of CGRP. The response to CGRP is inhibited by CGRP receptor antagonists
Vascular system
CGRP is a potent arterial and venous vasodilator and is frequently co-localized with SP.
Indeed,SPregulatesthevasodilatoractivityofCGRP,79 suggestingthatthereisanimportant
functional signiﬁcance to this co-localization. There are several mechanisms by which
CGRP produces vascular relaxation, as discussed in earlier reviews.80−82 It is accepted that
vasodilation is mediated via the CGRP1 receptor and blocked in a competitive manner by
CGRP8–37.
Depending on species and blood vessel type, the vasodilating properties of CGRP can
be endothelium dependent or independent, both cases involving an intracellular increase
in cAMP.49,83 In this signaling system, cAMP acts as a second messenger, subsequently
activatingcAMP-dependentkinaseandultimatelyregulatingionchannels,enzymeactivity,
and/or structural proteins.5,71,84−94
Inﬂammation
A wide range of proinﬂammatory stimuli can induce the release of neuropeptides from cu-
taneous sensory nerves, including heat, physical trauma, ultraviolet radiation, and irritant
chemicals. The release of these neuropeptides leads to neurogenic inﬂammation with ery-
thema and edema. CGRP is considered to be an important modulator of the inﬂammatory
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response after the activation of sensory nerves.95 The action of CGRP on edema formation
has been extensively studied, and interestingly, CGRP-like immunoreactivity (CGRP-LI)
around blood vessels increases in chronic inﬂammation.96 In a series of studies, a potenti-
ating action of CGRP in edema formation was demonstrated, but only when CGRP and SP
were administered concomitantly.5,79,97−99 Probably, CGRP’s potentiation of edema forma-
tion is due to its induced vasodilation and not due to its direct effect. The role of CGRP in
mast cell degranulation and histamine release has also been studied. The close anatomical
relationship between mast cells and sensory nerves in many organs suggests that there is a
physiological interaction between these two cell types.100 However, the capability of CGRP
for the activation of mast cells is less pronounced than that of SP.48,100 In fact, CGRP has
been reported to release little or no histamine.101
Wound healing
It has been postulated that sensory neuropeptides in general act as local growth factors.102
Thereisalsoincreasingevidencethatneuropeptidesparticipateinmanyoftheinﬂammatory
processesthatarecrucialfornormalwoundhealing.38 PlasmalevelsofCGRPareincreased
insofttissueinjuries103 andinpatientswithchroniccardiacfailureandsepsis,104 indicating
that CGRP may be another important peptide in chronic illness. Animal experiments have
shownthatratsdepletedwithsensoryneuropeptidesshowreducedinﬂammatoryresponses,
as well as poor wound healing and diminished skin integrity.105
CGRPseemstobeofimportanceintheformationofnewvesselsthroughtheinduction
of endothelial cell proliferation during pathophysiological events such as ischemia, inﬂam-
mation,andwoundhealing.106 Inthesurvivalofischemicdenervatedtissue,theimportance
of reinnervation of mainly CGRP-containing ﬁbers has been stressed.107 These data sug-
gest that the healing process is also related to the anti-inﬂammatory effects of CGRP, and
upregulation of CGRP binding sites are reported in selective brain areas (involved in the
integration of sensory information) following stress.108
Immune system
Neuropeptidesarecapableofinteractingwithalmostallcomponentsoftheimmunesystem.
CGRP is a potent anti-inﬂammatory mediator; it is thought to inhibit type 1 cytokines (eg,
interleukin [IL]-12 and interferon γ) and to enhance the production of IL-10, one of
the most immunosuppressive cytokines.109,110 Gomes et al12 observed anti-inﬂammatory
effects of CGRP in models of acute peritonitis, reducing the recruitment of neutrophils
induced by treatment with lipopolysaccharides. The anti-inﬂammatory effect of CGRP
is comparable with the proinﬂammatory effects of SP, bradykinin, and endothelin and
suggeststhatdifferentvasoactivepeptidescouldparticipateinoppositewaysonmacrophage
activation during local and systemic acute inﬂammation and possibly bacterial sepsis.12
CGRP AND BURNS
The reaction after a local burn injury is dependent on the temperature and duration of the
burn.111 Several experimental investigations have shown that the delayed phase in burn
inﬂammation is mediated by humoral and neurochemical factors, and pharmacological
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intervention could therefore be of clinical importance.112 The contribution of sensory
neuropeptides has been shown in the delayed phase. Several vasoactive neuropeptides have
been proposed as mediators of the delayed phase reaction.113
Althoughnotnecessarilyconnected,thesimilaritiesbetweenneurogenicinﬂammation
and the reactions after a burn injury are intriguing. The role of neurons in the response
after a burn injury was ﬁrst suggested by Sevitt,111 who observed that denervated skin
showed a higher (2–3˚C) threshold temperature at which plasma extravasation developed.
By applying a hot iron to the skin, he showed that a speciﬁc temperature initially induced
an erythema and if the application was prolonged, plasma extravasation could also be ob-
served. With decreasing temperatures, proportionally longer heat exposure was required
for the development of edema. In this context, it is interesting to note that the threshold
temperature for edema formation has been estimated to 45˚C111,114 and that this is similar
to threshold temperature for the activation of nociceptive ﬁbers in the skin.115 Furthermore,
in more severeburns, edemacanalsobeobservedinsubdermalstructuresandthishasbeen
correlated to subdermal temperatures of 41˚C to 45˚C during the time of exposure.111 Early
and delayed edema formation has been demonstrated in burns of different severity.111,116 In
moresevereburns,theearlypartisrapidinonsetandthedelayedpartisoftenindistinguish-
able from the early or abolished part due to stasis produced by the early massive edema
formation. In milder burns, the early part is less pronounced and sometimes followed by a
distinct delayed increase in edema formation occurring 4 to 8 hours postburn.111,116 This
latter effect can be observed after a well-deﬁned exposure of the skin to hot water (60◦C,
10 seconds).116
The ﬁrst evidence for the importance of nociceptive C-ﬁbers was obtained in 1983. It
has been shown that capsaicin pretreatment reduced edema formation after a mild (48˚C, 5
minutes) scalding injury,117 and that this edema was also reduced by an SP antagonist but
not by antihistamines.118,119
Burn injury leads to the release of SP and CGRP from nociceptive sensory
endings.120,121 CGRP and SP contribute to the spread of edema by acting directly on
venules to produce vasodilation. CGRP affects the regulation of local blood ﬂow, smooth
muscle tone, and glandular secretion. Siney and Brain122 conﬁrmed these ﬁndings in rat
dorsal skin by the use of selective SP and CGRP antagonists. SP and CGRP also seem to
play a role in the initial plasma extravasation observed after thermal injury in rat dorsal
skin.122
SP has a major role in the initial plasma extravasation after injury. Moreover, CGRP is
involved in mediating plasma extravasation for up to 15 minutes after the onset of thermal
injury.122 L¨ ofgrenetal123 demonstratedincreasedconcentrationsofCGRP-LIinaperfused
ratpawfollowingthermalinjury,andthermalinjuryresultedinaunilateralincreaseinblood
ﬂowparalleledbyanincreasedcontentofCGRP-LIandNKA-likeimmunoreactivityinpaw
perfusate.124 The thermally induced inﬂammation of the rat paw caused locally increased
perfusion,whichwascharacterizedby2phases.Notably,thesecondphasewassigniﬁcantly
reduced by pretreatment with NK1, NK2, or CGRP receptor antagonists, suggesting that
the secondary phase is neurogenically mediated.2
TheneuroendocrinesystemthroughthereleaseofCGRPandSPmayplayaroleinthe
pathogenesis of sepsis.104 High systemic CGRP levels were associated with lethal outcome
already at the onset of sepsis, whereas high SP levels were identiﬁed as late predictive
indicators of lethal outcome.104
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Onuoha and Alpar38 examined the concentration of sensory peptides in human ther-
mal injuries, on admission and 24 hours postadmission, and their role in the metabolic,
immunological, and inﬂammatory complications. Basal levels of CGRP and SP were sig-
niﬁcantly higher in patients with burn injuries than in the healthy control subjects.38 These
results support the concept that the neuroendocrine system through the release of CGRP
may play a critical role in the pathogenesis of sepsis.12,38,104
CONCLUSIONS AND FUTURE PERSPECTIVES
This review has summarized, and attempted to correlate, the inﬂammatory activities of
CGRP in burns. There have been previous reviews on the cardiovascular activities of
CGRP71,80,81 that relate to this fascinating peptide family.76,78 Its most important activity is
itspotencyinperipheralvasodilation.44,125−127 Severalstudieshaveshownthatsensorypep-
tides are released from peripheral nerve endings during a noxious or thermal stimulus, such
as a scald, and may thus contribute to the pathophysiology of burn injuries.12,38,103,119−124
This suggeststhat,as describedin this review,it probablyplays an important role in the reg-
ulationoftissueperfusion,inﬂammation,andhealingandtissuerepair.12,38,103,119−124 More
information regarding the concentration of CGRP in plasma in human burns is needed. It
will be interesting to follow plasma concentration of CGRP in patients with burn injuries,
frominjurytohealing,analyzingtheburnforextension,location,andcomplication(sepsis,
organ failure).
This may explain the impact of neurogenic inﬂammation in burn shock, and perhaps
CGRP levels can be used as a prognostic factor in the clinical setting. In this way, it may be
possible in the future to modulate the systemic response to burn to improve burn care. In
recent years, the synthesis of nonpeptides that are capable of antagonizing effects mediated
via the CGRP receptors has been a major advance.
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